Ceva has announced the launch of Zodon®, a flavoured clindamycin for dogs and cats.
Zodon is the only veterinary licensed flavoured clindamycin available in the UK.
Zodon is indicated for the treatment of infected wounds and abscesses in cats and dogs and oral cavity/dental infections caused by or associated with clindamycin-sensitive species of Staphylococcus spp, Streptococcus spp in dogs.
Rob Mclintock, Business unit manager for Ceva said: "Zodon is an exciting new product for Ceva, it is the first clindamycin on the market to offer flavoured presentations designed to help deal with compliance issues and help improve treatment success."
In a palatability study 98.3% of dogs took Zodon chicken flavoured tablets spontaneously. Ceva says the oral solution for cats and small dogs also offers easier administration with grilled meat flavouring and a graduated syringe.
Adelaide Ellerington, product manager for Ceva Animal Health said: "Zodon complements our existing antibiotic range perfectly. The whole range is designed specifically for veterinary use allowing veterinary surgeons to dose more accurately and improve patient compliance by offering flavoured tablets and solutions."
You can preorder Zodon now from Ceva - telephone 01494 781510 or email: cevauk@ceva.com - alternatively Zodon will be available from wholesalers at the start of next week.
Speaking at Improve International's OV Conference last week, Dr Wright cited increased pet travel and importation as key risk factors, including the growing number of rescued dogs arriving in the UK from countries in Europe and further afield.
Dr Wright highlighted the Rhipicephalus tick (Rhipicephalus sanguineus) as being a particular cause for concern, as it can transmit Ehrlichia canis, Anaplasma platys, Rickettsias, Babesia vogeli and Hepatozoon.
Dr Wright said that Ehrlichia canis and Anaplasma platys are among the most common tick-borne diseases in imported dogs, particularly those arriving from Eastern and Southern Europe. There were also three cases of Hepatozoon canis in 2018, caused by dogs ingesting Rhipicephalus ticks while grooming.
According to figures from a Bristol University Pet Travel survey, 54.5% of dog travel on the Pet Travel Scheme from the UK is to France with Southern European countries also popular destinations. These are all countries in which Rhipicephalus is present and on the increase. Dr Wright said that the ticks are moving north into Austria, Switzerland, Central France, Romania and Bulgaria.
During the last few months, he has also been alerted to ticks found on dogs coming in from North America, Latin America and Africa. These bring with them the risk of new diseases, including a variety of zoonotic rickettssial pathogens, such as Rickettsia Rickettsii, which causes Rocky Mountain Spotty Fever.
To address this issue Dr Wright urged vets to redouble their efforts on tick prevention. In particular, he recommended tick prevention pre/during and post travel, using products that offer rapid kill and repellency in order to reduce transmission, repellents being especially important in Leishmania infantum and Rhipicephalus-endemic countries.
Dr Wright recommended drilling clients and staff on tick removal and reminding them that finding a tick on a pet is not a failure as no product is 100% reliable and it is easy to miss them in long-haired dogs. He also suggested asking clients to take photos of any ticks they find on their pet while abroad so that their vet will know on their return what pathogens they may have been exposed to. If necessary, the Public Health England Tick Surveillance Scheme can help with identification.
Dr Wright suggested that legislation to enforce tick treatment on entry was a poor strategy used in isolation as pets would still be exposed while abroad and no product is completely reliable. It would be useful however, to raise awareness and show that we are taking the issue of tick-borne disease seriously.
He said: "We’re seeing a significant increase in pet travel and import a wider range of countries from which dogs are being imported and this is significantly increasing our exposure to exotic ticks.
"What’s news about this is that while you could argue that diseases such as Lyme Disease are ‘lifestyle’ diseases because people and dogs are exposed to our native ticks while out enjoying the countryside, the Rhipicephalus tick comes to your home, exposing you to a wealth of rickettsial diseases for the first time. We are already seeing instances of this in France, Germany and Scandinavia and, as pet travel continues to grow, the risk here will only increase. It’s equally possible that a dog with a native tick could travel aboard and return hosting a new pathogen.
"The only way to manage this risk is to provide consistent advice to the public and to support increased disease surveillance. Vigilance is key – assume that any travelling dog may have ticks and do not assume that because it is tick-treated, it’s a case of ‘job done.’"
He said: "Put the onus on clients - gently. Remind them to seek advice, to check for ticks and to keep tick treatments up to date. Also remind them to visit the practice with their dog as soon as possible on their return. If you do find exotic ticks, please send them to the Tick Surveillance Scheme for identification."
He added: "If you know an owner who is planning to adopt a dog from abroad, explain the risks to them and encourage them to adopt from the UK. If they are determined to go ahead, work with them to ensure that you reduce the risk of exotic ticks arriving with their new family members. The risk to human and animal health from an infestation should not be underestimated."
Elanco says OA is a condition which is estimated to affect one in four dogs, but it is often labelled by owners as "just old age". This, says the company, may lead to missed diagnosis and dogs not receiving the care they need.
To try and help address the issue, Elanco has partnered with the founder of Canine Arthritis Management, Hannah Capon and veterinary communications consultant, Zoe Belshaw to produce a number of online and in-practice tools.
The first of these is a worksheet to help veterinary surgeons explain the impact of OE on the client's dog, both in and outside the home. It provides a template for creating a tailored management plan and a guide to the home adaptations owners can make to help improve their dog's quality of life.
The company has also produced a infographic fact sheet which explains the subtle signs of OA, designed for vets and nurses to use as part of their regular interactions with owners.
Elanco has also designed a range of digital materials for veterinary practices to use on their websites and social media feeds to increase awareness of the condition among their online communities.
Hannah Capon said: "Arthritis affects every dog differently – a dog may be full of life but lame, quiet, unenthused and slow to move, or somewhere in-between.
"Home management needs to be tailored to each dog’s needs and adapted in the same way it would be for a person, to prolong life and minimise pain and further injury."
Lastly, Elanco has also produced a film in which Zoe Belshaw gives advice about the language and strategies veterinary surgeons can use to help improve communication with dog owners about OA.
Zoe said: "My research identified that many owners do recognise their arthritic dog has a problem before it’s diagnosed. Many will have seen that their dog is stiff, or ‘slowing down’ but they may not associate this with lameness, or pain.
"That’s why vets, nurses and practices play a critical role in raising awareness of how the condition impacts dogs every day."
To access the suite of assets visit: www.myelanco.co.uk
Norbrook is expanding its NSAID range with the launch of Loxicom Injection for cattle, pigs and horses.
Norbrook says the new product, which will be available to veterinary surgeons from mid-October, offers treatment for a range of symptoms including pneumonia, acute mastitis and calf scour in cattle, swine locomotor diseases such as lameness and MMA syndrome, acute and chronic musculo-skeletal disorders and equine colic.
Rebecca Pullon, Norbrook Product Manager said: "Loxicom is our tried and trusted NSAID range which has been available in suspension or injection for cats and dogs and which has proven exceptionally popular with veterinary practices. According to the GFK data, Norbrook is the most successful generic manufacturer of Meloxicam, by some distance.
"I am delighted that we can now extend this range to include a Loxicom Injection for Cattle, Pigs and Horses, which I am confident will prove equally as popular."
"As a bio-equivalent product, Loxicom Injection for cattle, pigs and horses is as effective as the pioneer product. There is a misperception that a bioequivalent product is somehow inferior to the pioneer product, which is untrue. In order to attain a license, a company must prove that a bio-equivalent product is at least as effective as the pioneer. With Loxicom Injection for cattle, pigs and horses, it comes with the added reassurance that it has been produced by Norbrook, a world leader in animal health and veterinary pharmaceuticals manufacture."
The affected batches are: IsoFlo 250 ml 58006XN, 60003XN, 59005XN, 60006XN, 61001XN, 60016XN, 60017XN, 61018XN, 61015XN, 61016XN, 61017XN, 6062216, 6062225, 6062226, 6062217, 6063738 and Isothesia 250ml 6062335, 6063318.
Manufacturer Zoetis says there were a small number of reports of veterinary surgeons having difficulty in re-sealing the bottles after initial opening as the thread on the screw cap had not been fully formed. This defect does not impact the safety and efficacy of the product for animal use but the concern was related to potential evaporation from opened bottles which did not re-seal fully when closed.
Veterinary surgeons are asked to return any unopened bottles to the wholesaler and dispose of any opened bottles in the usual way. They will be fully reimbursed for the stock.
Zoetis says it has already addressed this packaging issue at the manufacturing site so that new batches of the product are unaffected.
Practices requiring further information on the matter should call Zoetis Technical Services on 0845 300 8034.
James qualified from Glasgow University in 2002 before joining Rosemullion Veterinary Practice, a mixed practice in Falmouth, Cornwall, of which he became a Director in 2008.
In 2014, Rosemullion separated its farm and small animal work, whereupon James became Clinical Director of the new farm practice, Coast2Coast Farm Vets.
In 2015, following the acquisition of Rosemullion and Coast2Coast by CVS, he was appointed to the group's Farm and Equine Clinical Advisory Committees. These Committees comprise clinical staff from across the Farm and Equine Divisions and make decisions on important issues, including purchasing, advice and information for its clinical teams and investments in the latest equipment and facilities.
James said: "I’ll be spending time each week travelling around the UK, Ireland and Holland to visit our farm practices and meet with colleagues within CVS and from the wider farming and veterinary industries.
"During my first six months, I’ll be focusing on developing frameworks and policies that will enable our practices to guide clients through difficult issues, such as antimicrobial and anthelmintic resistance and to help them succeed in the highly competitive marketplace for both prescription and non-prescription medicines.
"I will also be creating a bespoke farm New Graduate Programme for young vets which all our farm practices will be able to access.
"I see an exciting opportunity for CVS Farm to become a major force in the sector and am looking forward to working with my new colleagues to bring this about."
The company behind the research shall remain nameless because whilst it has a great PR agency which produces some interesting press releases, the tight so-and-sos have never spent so much as a single bean supporting the VetSurgeon.org community with any advertising. And whilst we always publish stories that are of genuine importance and even the odd piece of PR propaganda-puff, we have to draw the line somewhere.
Where was I? Oh yes. 57 of the 100 veterinary surgeons (64 practice owners, 7 senior partners and 29 employed vets) surveyed by the unnamed company said they think their practice could do more to prevent the spread of infection.
79 said they are concerned that they are not consistently following correct hygiene protocols.
54 said they need more staff training and 53 said they want to be able to give staff more time between appointments to allow longer for more thorough disinfection of equipment and surfaces.
The company says its research suggests vets may need to do more to educate pet owners on the threats of poor hygiene and the spread of infection. Only 14 of the 100 veterinary surgeons surveyed believe that pet owners know enough about this, and pets not being vaccinated against disease was the second most common frustration vets felt about owners’ standards of pet care.
An unnamed spokesperson from the unnamed company said: "A busy vets practice is naturally focused on the care and health of its animal patients, however, hygiene standards are a vital aspect of this. With a full schedule of appointments, it can be difficult to effectively ensure all infection control procedures are covered. As a result, it’s easy for vets to overlook the important role laundry has to play as part of this process."
Incidentally, if you'd like to buy laundry equipment from a company that does support VetSurgeon.org, we recommend Eickemeyer.
Dr Russell, 64, who waived his right to attend the hearing, was convicted in 2023 of three offences: making indecent photographs of a child, possessing 2,280 prohibited images of a child and possessing 109 extreme pornographic images that included moving images that were grossly offensive.
After pleading guilty to making indecent photographs/pseudo-photographs of a child, possessing a prohibited image of a child, and possessing extreme pornographic image/images portraying sexual acts with an animal, Dr Russell was sentenced at Winchester Crown Court to a two-year community order, a 30-day Rehabilitation Activity Requirement, 150 hours of community service and a forfeiture and destruction order of Seagate Drive, Toshiba hard drive and Lenovo tablet.
In addition, he was required to register with the police for 5 years and made subject to a Sexual Harm Prevention Order for five years.
He was also required to pay prosecution costs of £425 and £60 victim surcharge.
Counsel for the College submitted to the Disciplinary Committee that the nature and circumstances of the offences rendered Dr Russell unfit to practise as a veterinary surgeon.
The Committee considered there to be several aggravating factors including, actual (albeit indirect) injury to an animal or child; the risk of harm to an animal or child; sexual misconduct; premeditated conduct; and, that the offences involved vulnerable children and animals.
Neil Slater, chairing the Committee and speaking on its behalf, said: “The Committee has reached the conclusion that Dr Russell’s behaviour is fundamentally incompatible with being a veterinary surgeon, namely grave offences of a sexual nature.
"Dr Russell’s behaviour was so serious that removal of professional status and the rights and privileges accorded to that status is considered to be the only means of protecting the wider public interest and of maintaining confidence in the profession.
“The Committee has not taken this decision lightly, and, lest it be misinterpreted, it has not taken it in order to satisfy any notional public demand for blame and punishment.
"It has taken the decision because, in its judgment, the reputation of the profession has to be at the forefront of its thinking and ultimately this is more important than the interests of Dr Russell.
"The decision is not simply based on the fact that these offences were of a sexual nature but because they were repeated over a significant period of time and at a time when Dr Russell must have known, on his own plea of guilty, that what he was doing was wrong.
"Further, the Committee can discern no evidence that Dr Russell has insight into the gravity of the offence he has committed.
"The Committee has therefore directed the Registrar to remove his name from the Register forthwith.”
Dr Russell has 28 days from being notified of his removal from the Register to lodge an appeal with Privy Council.
Supplies of the vaccine, which is indicated for the active immunisation for horses against equine arteritis, ran low at the end of last year when Zoetis' existing stock was due to expire without any new stock in place.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
VetSurgeon member Alex Gough MRCVS, Head of Medicine Referrals at Bath Veterinary Referrals, has published his second historical thriller, Bandits of Rome, available for pre-order now in paperback (£7.99) or Kindle (£1.99) from Amazon.
The book picks up the story of Gaius Valerius Carbo as he leaves Rome with his family for the Italian countryside, only to be set upon by masked bandits.
Alex's first thriller, Watchmen of Rome, went to the top of the Amazon bestseller charts and has achieved reader reviews of an average 4.4 out of 5 stars.
Apparently the more people that pre-order the book before the 26th August, the higher it'll go up the charts. So if this sounds like it could be up your street, buy it today and you'll give a colleague a helping hand up the ladder at the same time.
Alfaxan 10mg/mL solution for injection for dogs and cats is licensed as an induction agent prior to inhalation anaesthesia and as a sole anaesthetic agent for the induction and maintenance of anaesthesia for the performance of examination or surgical procedures. Jurox highlights that it has been safely used in patients from 12 weeks of age, for the induction of anaesthesia prior to delivery of puppies by caesarean section and for maintenance anaesthesia in procedures lasting up to an hour.
Jurox offers the following advice: "Part 1 (2) of Schedule 4 of the Veterinary Medicines Regulations states that 'if there is no authorised veterinary medicinal product' then the cascade may be followed. Alfaxan is an available and authorised veterinary medicinal product with very similar indications and therefore there is no clinical need to resort to non-licensed formulations of propofol, under cascade, for veterinary intravenous anaesthesia."
The company says that its UK team of veterinary surgeons will again respond proactively to the propofol shortage by delivering educational support to veterinary professionals and assisting them through the change to another veterinary licensed product for the anaesthesia of cats and dogs should they wish.
If you would like to discuss specific cases or need support using Alfaxan for the first time, contact Jurox on 0800 500 3171 or email alfaxan@jurox.co.uk
The RCVS statement, which can be read in full here, highlighted the fact that there is no body of evidence that homeopathy is effective and nor is it based on sound scientific principles. It should therefore be considered as complementary rather than alternative to treatments which are based on sound scientific principles, or for which there is a recognised evidence base.
In fact, the RCVS statement said nothing new. The principle that veterinary surgeons must first prescribe licensed medicines tested for safety and efficacy is enshrined in the Veterinary Medicines Regulations 2013, which say that if there is no veterinary medicine authorised in the United Kingdom for a condition in a particular species the veterinary surgeon responsible for the animal may treat with a veterinary medicine authorised for use in another animal species or for another condition in the same species, or, failing that, either a medicine authorised in the UK for human use, or a veterinary medicine authorised in another member state for use with any animal species in accordance with the Special Import Scheme, or a specially prepared (extemporaneous preparation or special) medicine, or exceptionally a medicine imported from outside the EU.
There are no homeopathic treatments listed by the VMD as 'authorised', just a handful of homeopathic preparations listed as 'registered', something which, as the BAHVS itself points out, means they have not been subjected to the same evaluation as authorised medicines or tested for efficacy.
The BAHVS is fond of using anecdote as evidence of efficacy (see the endorsements at the foot of this page: http://www.bahvs.com/), so one veterinary surgeon has been inviting colleagues to share their experiences of homeopathy causing harm on social media, in order to produce an infographic (pictured above right, click to enlarge) highlighting the very real harm caused when, for example, owners 'vaccinate' against parvo with homeopathic nosodes, only to have a dead litter on their hands.
The draft infographic can be found here.
Do you have a story to add to it? Share it here.
Ludivine, who graduated in 2008, has come over from America to take up the new post, having just completed a three-year residency at the University of Pennsylvania in Philadelphia.
She said: "I’m really enjoying working as part of a great team and working with the various different disciplines here.
"I’m passionate about my ECC speciality and I have a keen interest in respiratory diseases, trauma and acid base disturbances.
"I also like teaching and being updated about the most recent studies in ECC to ensure I can deliver the most up-to-date care possible for our patients."
Ludivine was born in France and originally studied at her home town university in Lyon, progressing to a rotating internship there after graduation.
In 2012, she worked as an emergency veterinary surgeon in several general practices across France and Switzerland, before moving to the United States in 2014 to see how ECC medicine was practiced overseas.
First, she undertook an ECC internship at the University of California, followed by a three-year residency at the University of Pennsylvania.
Away from work, Ludivine enjoys horse riding, running, work-outs and practising her skiing in the French Alps. She also has two dogs Dalhi her Golden Retriever and Baya her German Shepherd.
For more information, visit www.willows.uk.net/en-GB/specialist-services.
'Hany’s Heartbreak' was a gorily realistic representation of a dog’s heart infected with Dirofilaria Immitis, baked by vet students Anna Burrows, Caitlin Glover, Chloe Tredinnick and Liberty Daly.
It pulled in votes from all over the world including Australia and the US, Saudi Arabia, Germany, Italy and the Caribbean.
The winning bakers said: "We chose to bake this cake as we wanted to make something that we could make look as realistic as possible and as gruesome.
"Our parasitology lecturer, Hany, inspired us to use the D. Immitis parasite as our theme to promote the message of how detrimental and possibly fatal some animal parasites can be! We had a great time baking it and enjoyed the looks of disgust that people who saw it gave. We promise it tastes better than it looks! Our key message to everyone is to PLEASE WORM YOUR PETS!"
The categories for baking inspiration this year were Transport to Campus, Scrumptious Science, Blue Planet and a Showstopper section. Sir David Attenborough and Pixar characters Nemo and Dory were among the other stars of the show, with colourful cakes on an environmental theme also winning prizes.
One of this year’s judges was Dr Wendela Wapenaar, Associate Professor at the Nottingham Vet School. Wendela said: “It’s been another great year for the Sutton Bonington Bakeoff. It was impressive to see how some bakers took on the challenging topics for this year; winning cakes were covering topics such as global warming, environmental pollution in addition to the more gory aspects of veterinary medicine."
GRAM (Guidance for the Rational use of AntiMicrobials) is a 500-page guide written by a panel of 10 independent European experts from the fields of microbiology, pharmacology and dermatology, all of whom are specialists in internal medicine, surgery and epidemiology. Based on rational use with compliance at the forefront, GRAM provides tools for improved diagnosis and positive treatment outcomes.
The guide consists of 37 disease fact sheets, 29 practical recommendations and six reference synopses. It features a range of topics including:
Andy Forsyth, senior technical veterinary advisor at Ceva said: "Antimicrobial resistance continues to be a concern in both human and animal health. GRAM will help educate veterinary professionals on how they can play their part in creating sustainable antibiotic use."
To request a copy of GRAM or for further information on sustainable antibiotic use, contact your local Ceva Animal Health territory manager.
The CMA provisional decision was widely seen as less interventional than had been expected, largely demanding transparency over things like pricing, practice ownership and billing, which many practices had already implemented.
However, one provisional decision was that regardless of their status, all veterinary practices should inform owners that they can ask for a written prescription and explain that they may be able to have it fulfilled cheaper online.
Two of the largest online veterinary pharmacies are animed.co.uk, which is owned by CVS, and peddrugsonline, which is owned by IVC.
So in effect, the decision asked independent practices to direct their clients to competitor businesses.
What you might call a bitter pill to swallow.
In the light of the announcement, CVS issued a press release citing the "clarity" afforded by the CMA announcement and the fact that it does not think the CMA's proposed remedies will have a material impact, as factors behind its decision to seek a Main Market listing.
The company has also announced a £20m share buyback programme.
In addition to working as a clinician in private practice and for charity, Gudrun has worked in several veterinary-related roles in industry, both in management and as a consultant, as well as being the Chair for the British Veterinary Association’s Good Veterinary Workplace Working Group.
In the new role, Gudrun will work support the implementation of the British Veterinary Association’s Good Veterinary Workplaces Code across the business.
Gudrun said: “Having been heavily involved in the work leading up to the Good Veterinary Workplaces Code during my time at the British Veterinary Association, I can fully relate to the many pressures that veterinary workplaces are currently under.
"Through supportive action and using evidence-based tools, I believe we can make a positive and lasting difference.
“It’s an honour to join Vets4Pets as we begin to implement its many commitments to improving the industry.
"I am excited to work towards a positive future for veterinary workplaces and being able to work with Vets4Pets to build a well-resourced and accessible tool for practices to implement good veterinary workplaces will help our practices to attract and retain the best clinical talent.”
Duoflect contains a new formulation of fipronil and (s)-methoprene which, according to the company, offers a 100% longer duration of action against fleas in cats (eight weeks), and a 13% longer duration in dogs (nine weeks) than the market-leading fipronil combination.
Ceva says the Duoflect's duration of action against ticks is 150% longer in cats (5 weeks) and 50% longer it cats (six weeks) than the market-leading competitor.
Duoflect acts against both adult fleas on the animal and immature flea stages in the environment and it can also be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Duoflect is available in free-standing pipettes for easier administration and handling of the pet. The pipettes are packed in child-resistant aluminium blisters to reduce the risk of accidents at home.
Nicki Glen, marketing project manager for Duoflect at Ceva Animal Health said: "Recent research1 has revealed that two main factors in prescribing parasitic control products are the length of action and the increased efficacy against fleas.
"Duoflect's new strength formulation provides a longer duration of action than the market-leading fipronil combination, while its efficacy is proven through 13 recent laboratory and field trials1."
Duoflect is competitively priced and is available in boxes of three or six pipettes and in five presentations: small cats (1-5kg), large cats (>5kg) and small dogs (2-10kg) and medium dogs (10-20kg), large dogs (20-40kg) and extra large dogs (40-60kg). It is suitable for cats and dogs from eight weeks of age.
Ceva Animal Health has produced a range of supporting marketing materials including client leaflets.
For more information, contact your local Ceva Animal Health territory manager or call Ceva’s head office on 01494 781510.
Reference
The group, which was founded over 70 years ago, now employs over 300 people, more than 85% of whom are female. Many occupy senior and leadership positions: 6 out of 13 of the partners are female.
Wendy Furness, a Partner at Scarsdale Vets said: "Scarsdale Vets represents a microcosm of how women’s roles could be in a world of gender equality in business.
"Here we have people in every role that you can imagine, from client-facing roles such as client care advisors, vets and nurses, to people that make the business function happen, such as marketing and finance managers.
"We want women to be inspired to be who they want to be. There are many roles that some people still first think of as male dominated, such as surgeons and farm or equine vets.
"However, we at Scarsdale Vets are challenging assumptions like these and looking for opportunities to make all roles visible to women.”
Wendy added: "Having women in leadership and senior roles is essential if women at the start of their careers are to succeed. We can be there to inspire the next generation to strive for these positions, if that is what they want, and see that it is made possible. We can also stand up and be counted if and when bias based on gender is observed."
To mark International Women’s Day, Scarsdale Vets is filling its social media channels with positive images of women, working in the diverse roles within the practice, challenging stereotypes about the veterinary roles available to women, influencing others positively, and celebrating the successes of the women in their team.
https://www.facebook.com/ScarsdaleVets/posts/2097073290308906
Photo: Rose Jackson MRCVS, a farm animal vet at Scarsdale Markeaton. Courtesy Scarsdale Vets.
Evidence given to the Women and Equalities parliamentary committee by BUPA last year suggested that 900,000 women may have left the UK workforce in recent years as a result of menopausal symptoms.
With the veterinary profession increasingly female in composition it is hoped that the hub will support more women to stay in the profession and therefore retain their vital skills in the workforce.
Statistics from the Voice of the Veterinary Profession Spring 2023 survey showed that only 14% of vets are aware of a menopause policy at their workplace, while 46% say there is no policy and 39% are unsure.
The survey also revealed that only 59% of vets would feel confident supporting a colleague experiencing menopause.
The new menopause hub provides veterinary specific menopause content to support everyone working in practice including colleagues, managers and partners of people experiencing menopause.
BVA recently signed the Menopause Workplace Pledge – committing to take positive action to make sure everyone experiencing menopause is supported - and is now urging other veterinary employers to do the same.
British Veterinary Association Junior Vice President Anna Judson, said: “We know that menopause is of growing importance to our profession, with female vets now making up more than half the workforce, and we know that issues with managing menopause symptoms prompt a significant number of women to move away from clinical work.
“As part of our Good Veterinary Workplaces campaign we’re committed to supporting all veterinary staff affected by menopause, allowing them to remain in post, and to providing relevant resources to improve employer engagement in this area.
"We urge all veterinary workplaces to sign the pledge and consider what more they could be doing to support their staff in managing menopause symptoms in the workplace.”
BVA members experiencing menopause are also eligible for 3 months free access to the Stella app, which includes a personalised plan to manage your specific symptoms, real-life coach support, menopause resources, progress tracking, and a supportive community.
Content on the Stella app is created in collaboration with a range of clinicians and healthcare professionals and goes through a rigorous fact-checking and review process.
https://www.bva.co.uk/menopause-hub
Urging vets to 'get off their backsides and respond to a VMD consultation' on the introduction of a new POM-EA category (Vet Times, 19th October) is premature.
Contrary to the report, the VMD has not yet launched a formal consultation.
Jo Cawthorne from the VMD said: "In fact, we've only launched an informal consultation on a concept note amongst a small group of key stakeholders from the RCVS, BVA, RPSGB, AMTRA, AHDA and NOAH, in order to decide whether this is a viable idea and merits a formal consultation."
She added: "There is no need for vets to respond to a consultation which doesn't yet exist. If there is a formal consultation, it will be announced formally on our website and everyone will be given the opportunity to respond."
IVC was formed in 2011, the result of a merger of several independent veterinary hospitals. Under the leadership of David Hillier, and with backing from Summit Partners in 2014, it grew to over 300 practices before being acquired by the Swedish EQT Partners in January 2017.
In August last year the company merged with Evidensia Group, another veterinary corporate group with practices around Europe, bringing the total to more than 850 clinics and hospitals in eight countries.
EQT has reportedly now instructed Jefferies Investment Bank to auction the business in the first week of November.
No word yet on where the auction will take place. If you go, be careful not to scratch your nose at the wrong moment ("1.7 billion from the gentleman at the back. Yes, that's YOU, Sir.").
Protexin has announced that preliminary data from a clinical trial supports the use of Denamarin® to protect against lomustine (CCNU)-induced hepatotoxicity in dogs.
The study is being performed at the University of California-Davis, Veterinary Medical Teaching Hospital, and the initial results were recently presented at the American College of Veterinary Internal Medicine (ACVIM) Annual Forum. Marketed in the UK by Protexin, Denamarin is the combination of S-adenosylmethionine (SAMe) and silybin.
According to the company, most dogs treated with the chemotherapeutic agent CCNU experience liver enzyme elevation. Elevation of certain liver enzymes such as alanine transferase (ALT) is a key indicator of liver trauma; significant enzyme elevation may lead to a discontinuation, delay, or reduction in chemotherapy. The ongoing clinical trial was designed to evaluate Denamarin as a hepatoprotectant in dogs diagnosed with neoplasia that are undergoing CCNU therapy.
The trial consists of two groups of randomly assigned dogs. Dogs in Group 1 receive Denamarin beginning at the start of CCNU therapy. Group 2 dogs do not receive Denamarin unless they develop a Grade IV hepatotoxicity.
Results of a planned interim analysis completed on the first 30 dogs enrolled revealed that starting Denamarin when CCNU therapy was instituted (Group 1 dogs) appeared to provide hepatoprotection. While the mean post-therapy ALT elevation for Group 1 was 119 IU/L (p=0.1), for Group 2 dogs, the post-therapy ALT level was 815 IU/L (p=0.046). Chemotherapy was altered due to elevated liver enzymes in three Group 2 dogs but only one dog in Group 1.
Janine Barlow, Technical Manager at Protexin said: "We are extremely pleased by the initial findings of this research. The use of Denamarin with chemotherapy looks to help protect liver function allowing for successful completion of therapy and hopefully a longer, happier life for the pet. We look forward to the results of the full study."
Protexin says the SAMe and silybin in Denamarin support and maintain hepatic function by mechanisms including increasing levels of glutathione, the liver's main detoxifying agent; promoting protein synthesis; and stimulating bile flow. Denamarin is useful as part of a polymodal approach to the management of liver health.
Denamarin is available for both dogs and cats in an enteric-coated tablet.
Containing ceftiofur (50mg/ml) and ketoprofen (150mg/ml), Curacef Duo is presented in a ready-to-use suspension for injection at a low volume dosage – 1 ml/50kg – which is identical to short-acting ceftiofur alone.
Virbac says that Curacef Duo’s combined action can help to minimise production losses in calves and offer a quick return to production for dairy cows affected by bacterial BRD. It can also improve welfare by targeting infection, inflammation and pain all at once, while its ease of use and simple dosing help to increase compliance. Curacef Duo offers a zero milk withdrawal period and an eight day withdrawal period in meat.
Brigitte Goasduf MRCVS, Large Animal Product Manager at Virbac, said: "In creating the first 'two-in-one' combination of two tried and trusted actives, the antibiotic ceftiofur and NSAID ketoprofen, we are offering practitioners an alternative to the treatment of bacterial BRD.
"We believe that the benefits Curacef Duo offers in terms of efficacy, ease of use and action on inflammation and pain, will be valued by both practitioners and farmers."
DogStem has been shown to be effective, reducing pain and lameness and improving mobility and quality of life for three months to over twelve months following a single injection1,2.
In a prospective, randomised, double-blinded, placebo-controlled trial of DogStem, results showed that2:
TVM highlights how DogStem simplifies the process and reduces the cost of using stem cell therapy in practice because unlike previous therapies, it does not require require a surgical harvesting procedure to be carried out under general anaesthetic.
Helen Harrison, DogStem Technical Vet and Product Manager said: "Osteoarthritis is one of the most common diseases seen in veterinary practices and is challenging to manage.
"Conventional medical treatments typically address the symptoms rather than the underlying pathological processes.
"At the same time, local treatment options that slow progression of osteoarthritis have been limited and surgical interventions aren’t always possible or may be unrewarding.
"We’re delighted to be able to offer vets DogStem®, a stem cell product with a strong evidence base across numerous mobility and quality of life parameters.’
DogStem can be ordered from NVS, or direct from: www.dogstem.co.uk
References